SAMRAT PHARMACHEM
|
The Current P/E Ratio of SAMRAT PHARMACHEM is 48.47.
| Share Price | ₹245.3 | Feb 10,2026 |
| Market Cap | ₹76.0 Cr | |
| Earnings-TTM | ₹1.6 Cr | TTM-Standalone Results |
| Price/Earnings | 48.47x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of SAMRAT PHARMACHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹76.0 Cr] as on Feb 10,2026
(/) Earnings [ ₹1.6 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 48.47x ]
Thus, for SAMRAT PHARMACHEM , the investors are currently willing to pay 48.47 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of SAMRAT PHARMACHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of SAMRAT PHARMACHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of SAMRAT PHARMACHEM
PE Ratio Performance Analysis for SAMRAT PHARMACHEM
- SAMRAT PHARMACHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 16.94x.
- SAMRAT PHARMACHEM 's operated at median p/e ratio of 8.72x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, SAMRAT PHARMACHEM 's p/e ratio peaked in Mar2024 at 47.64x.
- SAMRAT PHARMACHEM 's p/e ratio hit its five-year low in Mar2023 of 6.89x.
How does SAMRAT PHARMACHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| SAMRAT PHARMACHEM | 1.57 | 48.47 | 76.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.24 | 409,698.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 65.94 | 163,866.0 |
| CIPLA LTD | 4,544.70 | 23.85 | 108,412.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 64.51 | 138,062.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.03 | 104,805.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.61 | 85,533.2 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.09 | 89,273.1 |
| LUPIN LTD | 4,347.53 | 23.17 | 100,736.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 18.55 | 65,186.3 |
| ABBOTT INDIA LTD | 1,508.95 | 38.47 | 58,041.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs SAMRAT PHARMACHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.09x |
| Max industry PE | 65.94x |
| Median industry PE | 37.24x |
| Average industry PE | 36.81x |
You may also like the below Video Courses